A Phase 2 Trial of Carfilzomib Consolidation After Autologous Stem Cell Transplantation for Multiple Myeloma(CARAMEL 2)
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 发起方
- Mayo Clinic
- 试验地点
- 3
- 主要终点
- Rate of complete response
研究概览
简要总结
This phase II trial studies how well carfilzomib and dexamethasone work in treating patients with multiple myeloma who previously underwent a stem cell transplant. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunosuppressive therapy, such as dexamethasone, may improve bone marrow function and increase blood cell counts. Giving carfilzomib together with dexamethasone may be an effective treatment for multiple myeloma.
详细描述
PRIMARY OBJECTIVES:
I. To assess the complete response (CR) rate with carfilzomib and dexamethasone consolidation following an upfront single stem cell transplant (SCT).
SECONDARY OBJECTIVES:
I. To assess the toxicity of carfilzomib and dexamethasone when used as consolidation therapy in patients post SCT.
II. To determine the progression free rate at 1 and 2 years post SCT. III. To evaluate progression-free survival and overall survival.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Creatinine =< 3 mg/dL
- •Absolute neutrophil count >= 1,000/uL
- •Platelet count >= 75,000/uL
- •Hemoglobin >= 8.0 g/dL
- •Previous diagnosis of symptomatic multiple myeloma (MM)
- •Received single autologous stem cell transplantation 60-120 days prior to registration
- •Received the autologous SCT =< 12 months of their diagnosis of myeloma to be eligible for the study
- •Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2
- •Recovered from toxicity of previous chemotherapy (excludes grade 1 neurotoxicity and hematological toxicity)
- •Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that the subject may withdraw consent at any time without prejudice to future medical care
- •Negative pregnancy test performed =< 7 days prior to registration, for women of childbearing potential only
- •Willingness to return to one of the enrolling institutions for follow-up (during the active monitoring phase of the study); NOTE: during the active monitoring phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-up
- •Measurable disease of multiple myeloma at the time of baseline values for disease assessment as defined by at least one of the following:
- •Serum monoclonal protein >= 1.0 g/dL
- •>= 200 mg of monoclonal protein in the urine on 24 hour electrophoresis
- •Serum immunoglobulin free light chain >= 10 mg/dL AND abnormal serum immunoglobulin kappa to lambda free light chain ratio
- •NOTE: for patients with no relapse prior to transplant, measurable disease at the time of diagnosis
- •NOTE: for patients who have had a disease relapse prior to transplant, measurable disease at the time of the most recent relapse immediately prior to transplant; NOTE: if the patient had treatment for the relapsed disease prior to transplant, the patient must have measurable disease at the time of relapse prior to this therapy
- •Willing to provide bone marrow and blood samples for correlative research purposes
排除标准
- •Prior allogeneic bone marrow/peripheral blood stem cell transplant
- •Evidence of disease progression post SCT at the time of consideration for the study enrollment
- •Myocardial infarction =< 6 months prior to registration
- •New York Heart Association (NYHA) class III or IV heart failure
- •Uncontrolled angina
- •Severe uncontrolled ventricular arrhythmias
- •Electrocardiographic (ECG) evidence of acute ischemia or active conduction system abnormalities; NOTE: prior to study entry, any ECG abnormality at screening has to be documented by the investigator as not medically relevant
- •Seroreactivity for human immunodeficiency virus (HIV), human T-cell lymphotrophic virus (HTLV) I or II, hepatitis B virus (HBV), or hepatitis C virus (HCV)
- •Other active malignancy requiring therapy; EXCEPTIONS: non-melanotic skin cancer or carcinoma-in-situ of the cervix; NOTE: if there is a history or prior malignancy, they must not be receiving other specific treatment for their cancer
- •Pregnant women or women of reproductive capability who are unwilling to use effective contraception
- •Nursing women
- •Men who are unwilling to use a condom (even if they have undergone a prior vasectomy) while having intercourse with any woman, while taking the drug and for 28 days after stopping treatment
- •Other co-morbidity, which would interfere with patient's ability to participate in the trial, e.g. uncontrolled infection, uncompensated lung disease
- •Concurrent chemotherapy, radiotherapy, or any ancillary therapy considered investigational; NOTE: bisphosphonates are considered to be supportive care rather than therapy, and are thus allowed while on protocol treatment
- •Known allergies to any of the components of the investigational treatment regimen or required ancillary treatments
研究组 & 干预措施
Treatment (carfilzomib, dexamethasone)
Patients receive carfilzomib IV over 30 minutes and dexamethasone PO on days 1, 2, 15, and 16. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
干预措施: laboratory biomarker analysis (Other)
Treatment (carfilzomib, dexamethasone)
Patients receive carfilzomib IV over 30 minutes and dexamethasone PO on days 1, 2, 15, and 16. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
干预措施: carfilzomib (Drug)
Treatment (carfilzomib, dexamethasone)
Patients receive carfilzomib IV over 30 minutes and dexamethasone PO on days 1, 2, 15, and 16. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
干预措施: dexamethasone (Drug)
结局指标
主要结局
Rate of complete response
时间窗: Up to 5 years
The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. Exact binomial 95% confidence intervals for the true success proportion will be calculated.
次要结局
- Overall survival(Time from registration to death due to any cause, assessed up to 5 years)
- Progression-free survival(Time from registration to progression or death due to any cause, assessed up to 5 years)
- Time to progression post SCT(Time from SCT to the earliest day with documentation of disease progression, assessed at 2 years post-SCT)
- Maximum grade for each type of adverse event(Up to 30 days after last day of treatment)